The effect of topical amphotericin B on inflammatory markers in patients with chronic rhinosinusitis: A multicenter randomized controlled study

Laryngoscope

Volumn 119, Issue 2, 2009, Pages 401-408

  Ebbens, Fenna A ^a   Georgalas, Christos ^a   Luiten, Silvia ^a   Van Dru Nen, Cornelis M ^a   Badia, Lydia ^b   Scadding, Glenis K ^b   Hellings, Peter W ^c   Jorissen, Mark ^c   Mullol, Joaquim ^d   Cardesin, Alda ^d   Bachert, Claus ^e   Van Zele, Thibaut P J ^e   Lund, Valerie J ^b   Fokkens, W J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d HOSPITAL CLÍNIC   (Spain)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Amphotericin B; Chemokines; Chronic disease; Cytokines; Double blind method; Fungi; Human; Intranasal administration; Nasal polyps; Prospective study; Randomized controlled trial; Rhinosinusitis

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; EMCUR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PLACEBO; RHINICUR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIFUNGAL AGENT; SIGNAL PEPTIDE;

ADULT; ARTICLE; CHRONIC DISEASE; CHRONIC SINUSITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; INFLAMMATORY CELL; MALE; MULTICENTER STUDY; NOSE MUCUS; NOSE POLYP; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOSINUSITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND HEALING; CHI SQUARE DISTRIBUTION; IMMUNOLOGY; INFLAMMATION; INTRANASAL DRUG ADMINISTRATION; MICROBIOLOGY; MIDDLE AGED; NASAL LAVAGE; NONPARAMETRIC TEST; RHINITIS; SINUSITIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, TOPICAL; ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHEMOKINES; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NASAL LAVAGE; NASAL POLYPS; PROSPECTIVE STUDIES; RHINITIS; SINUSITIS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 63249134498     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20064     Document Type: Article

References (28)

1. Fokkens WJ, Lund VJ, Mullol J., et al. European position paper on rhinosinusitis and nasal polyps 2007. Rhinology 2007; 45 (suppl) :1-139.
2. Ponikau JU, Sherris DA, Kern EB, et al. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc 1999; 74:877-884.
3. Ebbens FA, Georgalas C., Rinia AB, van Drunen CM, Lund VJ, Fokkens WJ. The fungal debate: where do we stand today? Rhinology 2007; 45:178-189.
4. Ebbens FA, Fokkens WJ. The mold conundrum in chronic rhinosinusitis: where do we stand today? Curr Allergy Asthma Rep 2008; 8:93-101.
5. Ponikau JU, Sherris DA, Weaver A., Kita H. Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, double-blind pilot trial. J Allergy Clin Immunol 2005; 115:125-131.
6. Ponikau JU, Sherris DA, Kita H., Kern EB. Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis. J Allergy Clin Immunol 2002; 110:862-866.
7. Ricchetti A., Landis BN, Maffioli A., Giger R., Zeng C., Lacroix JS. Effect of anti-fungal nasal lavage with amphotericin B on nasal polyposis. J Laryngol Otol 2002; 116:261-263.
8. Weschta M., Rimek D., Formanek M., Polzehl D., Podbielski A., Riechelmann H. Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: a randomized, double-blind clinical trial. J Allergy Clin Immunol 2004; 113:1122-1128.
9. Ebbens FA, Scadding GK, Badia L., et al. Amphotericin B nasal lavages: not a solution for patients with chronic rhinosinusitis. J Allergy Clin Immunol 2006; 118:1149-1156.
10. Rinia AB, Kostamo K., Ebbens FA, van Drunen CM, Fokkens WJ. Nasal polyposis: a cellular-based approach to answering questions. Allergy 2007; 62:348-358.
11. Cervin A., Wallwork B. Macrolide therapy of chronic rhinosinusitis. Rhinology 2007; 45:259-267.
12. Lund VJ, Mackay IS. Staging in rhinosinusitus. Rhinology 1993; 31:183-184.
13. Wildfeuer A., Seidl HP, Paule I., Haberreiter A. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 1998; 41:309-319.
14. Kfoury AG, Smith JC, Farhoud HH, et al. Adjuvant intrapleural amphotericin B therapy for pulmonary mucormycosis in a cardiac allograft recipient. Clin Transplant 1997; 11:608-612.
15. Leu HS, Huang CT. Clearance of funguria with short-course antifungal regimens: a prospective, randomized, controlled study. Clin Infect Dis 1995; 20:1152-1157.
16. Jornot L., Rochat T., Lacroix JS. Nasal polyps and middle turbinates epithelial cells sensitivity to amphotericin B. Rhinology 2003; 41:201-205.
17. Jornot L., Rochat T., Caruso A., Lacroix JS. Effects of amphotericin B on ion transport proteins in airway epithelial cells. J Cell Physiol 2005; 204:859-870.
18. Shin SH, Ye MK. Effects of topical amphotericin B on expression of cytokines in nasal polyps. Acta Otolaryngol 2004; 124:1174-1177.
19. Weschta M., Rimek D., Formanek M., Podbielski A., Riechelmann H. Effect of nasal antifungal therapy on nasal cell activation markers in chronic rhinosinusitis. Arch Otolaryngol Head Neck Surg 2006; 132:743-747.
20. Roponen M., Seuri M., Nevalainen A., Randell J., Hirvonen MR. Nasal lavage method in the monitoring of upper airway inflammation: seasonal and individual variation. Inhal Toxicol 2003; 15:649-661.
21. Heikkinen T., Shenoy M., Goldblum RM, Chonmaitree T. Quantification of cytokines and inflammatory mediators in samples of nasopharyngeal secretions with unknown dilution. Pediatr Res 1999; 45:230-234.
22. Menten P., Wuyts A., Van DJ. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002; 13:455-481.
23. Domachowske JB, Bonville CA, Gao JL, Murphy PM, Easton AJ, Rosenberg HF. The chemokine macrophage-inflammatory protein-1 alpha and its receptor CCR1 control pulmonary inflammation and antiviral host defense in paramyxovirus infection. J Immunol 2000; 165:2677-2682.
24. Aliberti J., Reis e Sousa C., Schito M., et al. CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat Immunol 2000; 1:83-87.
25. Olszewski MA, Huffnagle GB, McDonald RA, et al. The role of macrophage inflammatory protein-1 alpha/CCL3 in regulation of T cell-mediated immunity to Cryptococcus neoformans infection. J Immunol 2000; 165:6429-6436.
26. Taccariello M., Parikh A., Darby Y., Scadding G. Nasal douching as a valuable adjunct in the management of chronic rhinosinusitis. Rhinology 1999; 37:29-32.
27. Bachmann G., Hommel G., Michel O. Effect of irrigation of the nose with isotonic salt solution on adult patients with chronic paranasal sinus disease. Eur Arch Otorhinolaryngol 2000; 257:537-541.
28. Rabago D., Zgierska A., Mundt M., Barrett B., Bobula J., Maberry R. Efficacy of daily hypertonic saline nasal irrigation among patients with sinusitis: a randomized controlled trial. J Fam Pract 2002; 51:1049-1055.